ALICIA PANKO: Open Payments
NPI 1548840341 · ABINGDON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,718 in 114 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $345 · 2025 $2,718
Food & beverage: $2,634Education: $84
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 16 | $495 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $349 |
| ABBVIE INC. | 18 | $349 |
| Madrigal Pharmaceuticals | 12 | $289 |
| Ardelyx, Inc. | 11 | $284 |
| PFIZER INC. | 10 | $198 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $191 |
| QOL Medical, LLC | 4 | $123 |
| Lilly USA, LLC | 5 | $111 |
| Ipsen Biopharmaceuticals, Inc | 3 | $90 |
Products named: TREMFYA, REZDIFFRA, IBSRELA, ENTYVIO, CREON, XIFAXAN, VELSIPITY, Sucraid.
Industry payments across MD — which companies pay providers there.
